Accueil   Diary - News   All news ERYTECH presents new preclinical anti-tumor data

ERYTECH presents new preclinical anti-tumor data

ERYTECH presents new preclinical anti-tumor data on erymethionase at AACR 2017

 

ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced the presentation of new anti-tumor data supporting the Company’s preclinical product erymethionase (ERY-MET) at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held April 1 – 5, 2017 in Washington, D.C.


Read the press release

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree